Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

Prior treatment

• Myocardial infarction, stroke, hospitalization for heart failure, unstable angina pectoris or transient ischemic attack within 30 days prior to the day of screening.
• Bariatric surgery prior to screening or planned bariatric surgery within the trial time course.
• Treatment with any GLP-1 receptor agonist within 90 days prior to the day of screening.
• Treatment with continuous subcutaneous insulin infusion
• Presence of acute pancreatitis within the last 180 days prior to screening.
• Any disorder, including severe psychiatric disorder, suicidal behavior within 90 days before screening, and suspected drug abuse, which in the investigator´s opinion might jeopardize subject´s safety or compliance with the protocol.
  • RELAXING ELIGIBILITY OF THE STEP-HFpEF DM TRIAL
• Prior treatment with any GLP-1-RA
• Treatment with continuous subcutaneous insulin infusion

Other illness

• Any other condition judged by the investigator to be the primary cause of dyspnea (such as heart failure due to restrictive cardiomyopathy or infiltrative conditions (e.g. amyloidosis), hypertrophic obstructive cardiomyopathy, primary pulmonary arterial hypertension, chronic obstructive pulmonary disease, right heart failure due to pulmonary disease, complex congenital heart disease, anemia, or more than moderate heart valve disease).
• History of type 1 diabetes (history of gestational diabetes is allowed).
• Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
• End-stage renal disease or chronic or intermittent hemodialysis or peritoneal dialysis.
• Presence or history of malignant neoplasm within 5 years prior to the day of screening. Basal and squamous cell cancer and any carcinoma in-situ are allowed.
• History of type 1 diabetes mellitus
• End-stage renal disease or chronic or intermittent hemodialysis or peritoneal dialysis
• History of bariatric surgery
• History of nursing home admission
• Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous-cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer) for less than 5 years

Other

• Systolic blood pressure \> 160 mmHg at screening.
• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy.
• Recurrent severe hypoglycemic episodes within the last year as judged by the investigator.
• History or presence of chronic pancreatitis.
• Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.
• Pregnant female or breast-feeding
• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy
• Multiple endocrine neoplasia type 2 or medullary thyroid carcinoma

• Male or female, age above or equal to 18 years at the time of signing informed consent.
• BMI ≥ 30.0 kg/m2
• NYHA Class II-IV
• LVEF ≥ 45%
• No hospitalizations due to heart failure between screening (V1) and randomization (V2)
• At least one of the following:
• If BMI \<35.0: NT-proBNP ≥ 220 pg/mL (for patients with sinus rhythm) or NTproBNP ≥660 pg/mL (for patients with persistent/permanent atrial fibrillation); if BMI ≥ 35.0: NT-proBNP ≥ 125 pg/mL (for patients with sinus rhythm) or NTproBNP ≥ 375 pg/mL (for patients with persistent/permanent atrial fibrillation) at screening (NT-proBNP analyzed by the central laboratory) in combination with at least one of the following (documented by echocardiography within 12 months prior to or at screening): i. Septal é \< 7cm/sec or lateral é \< 10 cm/sec or average E/é ≥ 15 ii. PA systolic pressure \>35mmHg iii. Left atrial (LA) enlargement (LA width ≥3.8 cm or LA length ≥ 5.0cm or LA area ≥ 20.0cm2 or LA volume ≥ 55mL or LA volume index ≥29mL/m2) iv. LV hypertrophy with septal thickness or posterior wall thickness ≥1.2cm
• Hospitalization with a primary diagnosis of decompensated heart failure which required intravenous loop diuretic treatment, within the previous 12 months in combination with at least two of the following (documented by echocardiography within 12 months prior to or at screening): i. Septal é \< 7cm/sec or lateral é \< 10cm/sec or average E/é ≥15 ii. PA systolic pressure \>35mmHg iii. LA enlargement (LA width ≥3.8cm or LA length ≥ 5.0cm or LA area ≥20.0cm2 or LA volume ≥ 55mL or LA volume index ≥ 29mL/m2) iv. LV hypertrophy with septal thickness or posterior wall thickness ≥1.2cm
• Diagnosed with T2D ≥ 90 days prior to the day of screening.
• Subject treated with diet, exercise, and/or antidiabetic treatment\* according to local label in stable dosing for at least 30 days prior to screening: o \*OAD(s): unchanged drug(s), dose and dosing frequency o \*Insulin(s): unchanged regimen (basal, basal + bolus, premix combination) with stable total daily insulin dose as judged by the investigator
• Men or women ≥ 18 years old
• History of type 2 diabetes mellitus
• BMI ≥ 27.0 kg/m2
• Heart failure
• Preserved ejection fraction

Criteria the registry did not label

• Eligible cohort entry dates:
• Optum: Study period between January 1, 2018 to November 30, 2024. Marketscan: Study period between January 1, 2018 to December 31, 2023. Medicare: Study period between January 1, 2018 to December 31, 2020.
• FOLLOWING ELIGIBILITY OF THE STEP-HFpEF DM TRIAL